Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Dyne Therapeutics IncDYN-12.430.004.13-14.38-52.46%-19.40%55.60$27.22$56.3832,101$34.61

Detail of Dyne Therapeutics Inc

 
CEO
Mr. John G. Cox M.B.A.
Employees
141
Industry
Biotechnology
Sector
Healthcare
Market cap
$3B

Company details

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Dyne Therapeutics Inc
DYN • XNGS • US
$34 .61
+24.73 (250.56%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$2.78
Margin profit
0.00%
52 week low
$6.63
52 week high
$47.310001
50-day simple moving average
$35.22
200-day simple moving average
$35.24
Percent held by insiders
0.39%
Percent held by institutions
112.79%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
DYN +250.56%
eps change
DYN 0.00%